Senior Scientist
CurrentJoined Alexion AstraZeneca with portfolio acquisition of Pfizer’s preclinical rare disease gene therapies. Program lead for an AAV gene therapy program in rare neurology. Contributing to discovery biology efforts in rare diseases with neurological and metabolic indications.